IL15 and T-cell Stemness in T-cell–Based Cancer Immunotherapy
نویسندگان
چکیده
منابع مشابه
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.
Preclinical models revealed that the immune system can mediate rejection of established tumors, but direct evidence in humans has been limited to largely immunogenic tumors, such as melanoma. The recent success of immune checkpoint inhibitors and adoptive T-cell transfer immunotherapy in clinical trials has instilled new hope for the use of T-cell immunotherapy in the treatment of cancer. IL15,...
متن کاملSubcutaneous Immunotherapy and Synbiotic Combination Shift T-Helper 1 and Cytotoxic T Cells in Allergic Rhinitis
Background: Synbiotics have been used in the prevention and treatment of various immunological diseases. We aimed to investigate the synergistic clinical and immunologic effects of synbiotics and subcutaneous allergen immunotherapy (SCIT) combination in patients with allergic rhinitis. Materials and Methods: Nineteen individuals with all...
متن کاملT-cell Exhaustion and Cancer Immunotherapy
Contributors: 1Associate Professor, Department of Oral Pathology & Microbiology, Faculty of Dental Sciences, MS Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India; 2Professor and HOD, Department of Oral Pathology & Microbiology, Faculty of Dental Sciences, MS Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India; 3Postgraduate Student, Department of Oral Pathology...
متن کاملAdoptive T Cell Immunotherapy for Cancer
Harnessing the immune system to recognize and destroy tumor cells has been the central goal of anti-cancer immunotherapy. In recent years, there has been an increased interest in optimizing this technology in order to make it a clinically feasible treatment. One of the main treatment modalities within cancer immunotherapy has been adoptive T cell therapy (ACT). Using this approach, tumor-specif...
متن کاملAdvancing Chimeric Antigen Receptor-Engineered T-Cell Immunotherapy Using Genome Editing Technologies: Challenges and Future Prospects
Chimeric antigen receptor engineered-T (CAR-T) cells also named as living drugs, have been recently known as a breakthrough technology and were applied as an adoptive immunotherapy against different types of cancer. They also attracted widespread interest because of the success of B-cell malignancy therapy achieved by anti-CD19 CAR-T cells. Current genetic toolbox enabled the synthesis of CARs ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Research
سال: 2015
ISSN: 0008-5472,1538-7445
DOI: 10.1158/0008-5472.can-15-1498